ARCHIVES

FDA cancer therapeutics review split among three units in reorganization.

This article is from The Cancer Letter archive.

Vol. 29 No. 37 | October 10, 2003

Download PDF Visit The Full Archive

Related Articles

QOL With Femara Comparable To Placebo, Analysis Finds

December 26, 2003

Action Plan Steering committee votes 13-0 To Return $14 Million To NCI for Research

November 15, 1996

Organ Systems Program Success With Concepts Continues as DBD, DCE Boards Okay Five More

July 3, 1987

NCAB Approves New Nutrition Task Force With Earmarked Funds

May 28, 1982

FDA Approves Abraxane And Alimta for NSCLC

October 26, 2012

Non-Chemo Agents Added To Regimens For Lymphomas

January 26, 2007